Exakte Wirkstoffkennungen und zitierbare Passagen zu Wechselwirkungen, Gegenanzeigen und Nebenwirkungen.
Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
System Organ Common Uncommon Rare Very rare, not
Class known*
Blood and the Thrombocytopenia, Neutropenia, Thrombotic
lymphatic system leucopenia, including thrombocytopenic
disorders eosinophilia severe purpura (TTP) (see
neutropenia section 4.4), aplastic
anaemia, pancytopenia,
agranulocytosis, severe
thrombocytopenia,
acquired haemophilia
A, granulocytopenia,
anaemia
Cardiac disorders Kounis syndrome
(vasospastic allergic
angina / allergic
myocardial infarction)
in the context of a
hypersensitivity
reaction due to
clopidogrel*
Immune system Serum sickness,
disorders anaphylactoid
reactions,
cross-reactive drug
hypersensitivity among
thienopyridines (such
as ticlopidine,
prasugrel) (see
section 4.4)*, insulin
autoimmune
syndrome,
which can lead to
severe hypoglycemia,
particularly in patients
with HLA DRA4
subtype (more frequent
in the Japanese
population)*
Psychiatric Hallucinations,
disorders confusion
Nervous system Intracranial Taste disturbances,
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
10
System Organ Common Uncommon Rare Very rare, not
Class known*
disorders bleeding (some ageusia
cases were
reported with fatal
outcome),
headache,
paraesthesia,
dizziness
Eye disorders Eye bleeding
(conjunctival,
ocular, retinal)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Ear and labyrinth Vertigo
disorders
Vascular disorders Haematoma Serious hemorrhage,
hemorrhage of
operative wound,
vasculitis, hypotension
Respiratory, Epistaxis Respiratory tract
thoracic and bleeding (haemoptysis,
mediastinal pulmonary
disorders hemorrhage),
bronchospasm,
interstitial
pneumonitis,
eosinophilic
pneumonia
Gastrointestinal Gastrointestinal Gastric ulcer and Retroperitoneal Gastrointestinal and
disorders hemorrhage, duodenal ulcer, hemorrhage retroperitoneal
diarrhoea, gastritis, vomiting, hemorrhage with fatal
abdominal nausea, outcome, pancreatitis,
pain, dyspepsia constipation, colitis (including
flatulence ulcerative or
lymphocytic colitis),
stomatitis
Hepato-biliary Acute liver failure,
disorders hepatitis, abnormal
liver function test
Skin and Bruising Rash, pruritus, skin Bullous dermatitis
subcutaneous tissue bleeding (purpura) (toxic epidermal
disorders necrolysis, Stevens
Johnson Syndrome,
erythema multiforme,
acute generalised
exanthematous
pustulosis (AGEP)),
angioedema, drug -
induced
hypersensitivity
syndrome, drug rash
with eosinophilia and
systemic symptoms
(DRESS), rash
erythematous or
exfoliative, urticaria,
eczema, lichen planus
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
11
System Organ Common Uncommon Rare Very rare, not
Class known*
Reproductive Gynaecomastia
systems and breast
disorders
Musculoskeletal, Musculo-skeletal
connective tissue bleeding
and bone disorders (haemarthrosis),
arthritis, arthralgia,
myalgia
Renal and urinary Haematuria Glomerulonephritis,
disorders blood creatinine
increased
General disorders Bleeding at Fever
and administration puncture site
site conditions
Investigations Bleeding time
prolonged,
neutrophil count
decreased, platelet
count decreased
* Information related to clopidogrel with frequency “not known”.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It
allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare
professionals are asked to report any suspected adverse reactions via the national reporting system
listed in Appendix V.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Version 2025-06-23T11:55:00Z · SHA-256 77bedbd07ba7109037505e509b70d3e89cce68a41661a537751991f1f383eb00 · Passage 42f7144177697b690f59b1bda795c3fd216297691cf296a2e1269a137feab3cd · Zeichen 13494–13849 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.